Quick Facts
- Eligibility Expansion: Medicare now includes non-insulin users with Level 2 or Level 3 hypoglycemia or those with documented needle phobia.
- Cost Cap (Insulin): A $35 per month maximum applies for all covered insulin through Medicare plans, regardless of the delivery system.
- 2026 Spending Cap: Beneficiaries under Part D will see a new $2,100 annual out-of-pocket limit on prescription drug costs.
- Maintenance Rule: To keep your coverage active, a mandatory follow-up visit with your healthcare provider is required every 6 months.
- Approved Hardware: Current covered models include Dexcom G6, Dexcom G7, FreeStyle Libre 2, FreeStyle Libre 3, and the Eversense implantable system.
To qualify for Medicare CGM coverage, you must have a diagnosis of diabetes and a prescription from a healthcare provider. Medicare covers devices that are FDA-approved for making treatment decisions or those used in conjunction with an insulin pump. Eligibility has expanded to include patients on insulin-intensified regimens and those with a history of hypoglycemia, even if they do not use insulin, provided they meet specific CMS guidelines for continuous glucose monitors.
Is a CGM Right for You? Self-Assessment Checklist
Determining how to qualify for a CGM under Medicare 2024 rules begins with a goal-based timing approach. For many seniors, the transition to real-time glucose monitoring is a response to specific clinical milestones rather than just a desire for new tech. The Centers for Medicare & Medicaid Services (CMS) has lowered the barriers, but you still need to demonstrate a clinical need centered on Type 2 diabetes management or Type 1 care.
If you are considering this technology, use the following self-verification criteria to see if you meet the threshold for coverage:
Clinical Eligibility Self-Verification
- Have you experienced Level 2 hypoglycemia (glucose levels below 54 mg/dL)?
- Have you had a Level 3 hypoglycemic event requiring assistance from another person?
- Do you have a documented history of hypoglycemia unawareness, where you cannot feel your blood sugar dropping?
- Are you currently on an insulin-intensified regimen (using any type of insulin)?
One common hurdle readers face is the Success Paradox. Patients often worry that if their A1C improves because they are using a CGM, Medicare will decide they no longer "need" the device and revoke coverage. Fortunately, Medicare CGM eligibility criteria are designed to reward health stability. Once you qualify, maintaining your health does not disqualify you from the benefit, provided you continue to see your doctor every six months to document that the CGM is the reason for your success.
When preparing for your next appointment, consider these questions to ask your doctor about Medicare CGM coverage: Is my current hypoglycemia documented in my medical records as Level 2? Do we have a Certificate of Medical Necessity on file for the specific brand of monitor I prefer?
Expanded Eligibility: Non-Insulin Users and Special Cases
In a landmark shift, the requirement for "multiple daily injections" of insulin has been removed. This means that Medicare CGM coverage now extends to a much broader population. Under the expanded 2024 guidelines, Medicare covers CGMs for beneficiaries with Type 2 diabetes who use any type of insulin or have a history of problematic hypoglycemia.
This change is particularly significant for the estimated 2 million Medicare beneficiaries who are now eligible to use these monitors. Beyond insulin use, CMS Local Coverage Determination now recognizes "needle phobia" or trypanophobia as a valid clinical indicator for CGM use in certain diabetic patients. If the physical act of finger-sticking prevents you from managing your condition effectively, your doctor may be able to use this as a basis for your prescription.
This expansion acknowledges that Type 2 diabetes management is a complex, 24-hour-a-day job. Whether you are using a basal insulin or managing your levels through other pharmacological means, the ability to see trends in real time can prevent the dangerous "highs" and "lows" that lead to emergency room visits.
Financial Breakdown: Part B vs. Part D and the 2026 Cap
Understanding your costs requires a look at how Medicare categorizes your supplies. Most continuous glucose monitors are billed as Durable Medical Equipment under Medicare Part B. However, some beneficiaries may receive their supplies through their Part D pharmacy benefit, depending on their specific plan and the type of device.
| Feature | Medicare Part B (DME) | Medicare Part D (Pharmacy) |
|---|---|---|
| Typical Billing | Standard 20% coinsurance after deductible | Tiered copayments based on plan |
| Coverage Type | Durable Medical Equipment | Prescription drug benefit |
| Out-of-Pocket Cap | No annual cap (unless you have Medigap) | $2,100 annual cap starting in 2026 |
| Billing Cycle | 90-day cycles as of Jan 1, 2024 | Monthly or 90-day supply |
There are significant Medicare Part B vs Part D CGM coverage differences that will become even more pronounced in the coming years. Thanks to the Inflation Reduction Act, the Medicare Part D out of pocket cap for CGM supplies 2026 will be a game-changer for many. Starting in January 2026, Part D beneficiaries will have a $2,100 annual limit on what they pay for prescription drugs and covered supplies. If your CGM is covered under Part D, this provides a major financial safety net.
Furthermore, effective January 1, 2024, the CMS transitioned from a month-to-month billing cycle to 90-day billing cycles for CGM supplies. This streamlining is intended to reduce administrative headaches and ensure that patients don't run out of sensors or transmitters due to paperwork delays.
Essential Paperwork: Medicare CGM Documentation Requirements
Even if you meet the clinical criteria, the approval process relies heavily on specific administrative steps. Your doctor must provide detailed Medicare CGM documentation requirements to ensure your claim is not denied. This begins with the HCPCS codes: E2103 for the CGM receiver and A4239 for the monthly supply allowance (sensors and transmitters).
To stay compliant and ensure continuous coverage, follow this Compliance Calendar:
- Initial Consultation: Doctor documents the diabetes diagnosis and the clinical need for frequent glucose adjustments.
- Certificate of Medical Necessity: Your provider submits a CMN directly to the equipment supplier.
- Month 1-5: Actively use the device and sync data to your clinic if possible.
- 6-Month Mark: Conduct a follow-up visit (in-person or via telehealth) to document that the CGM is improving your glycemic control.
- Ongoing: Repeat the provider visit every 6 months to maintain the active prescription.
If you are wondering what documentation do I need for Medicare CGM approval, the most critical piece is the written order and the physician's notes showing that you (or your caregiver) have been trained on the device. Additionally, if your equipment is broken or no longer functional, replacement documentation must show that the device is out of its five-year useful lifetime or was damaged beyond repair. A prior authorization process may be required by certain Medicare Advantage plans, so always check with your insurance carrier before ordering.
Hardware Comparison: Dexcom vs. FreeStyle Libre
Medicare does not cover every gadget on the market, but it does cover the industry leaders. When looking at Medicare covered continuous glucose monitors Dexcom vs Freestyle Libre, the choice often comes down to personal lifestyle and whether you use an insulin pump.
The Dexcom G6 and G7 are highly popular for their integration with "looping" systems and insulin pumps. The Dexcom G7 is smaller and has a faster warm-up time than its predecessor. On the other hand, the Abbott FreeStyle Libre 2 and 3 are known for their slim profile and ease of application. Both brands offer real-time glucose monitoring that sends alerts to a standalone receiver or a smartphone.
Note that Medicare requires you to have a "therapeutic" CGM. This means the device must be FDA-approved to replace a standard blood glucose monitor for making treatment decisions (like dosing insulin). While you can use your smartphone to view your data, Medicare Part B typically requires the purchase of the manufacturer’s standalone receiver/reader to meet the definition of Durable Medical Equipment.
FAQ
Does Medicare pay for continuous glucose monitors?
Yes, Medicare covers continuous glucose monitors for beneficiaries with diabetes who meet specific clinical criteria. They are typically covered as Durable Medical Equipment under Part B, though some Part D plans may also offer coverage.
What are the Medicare eligibility requirements for a CGM?
Beneficiaries must have a diabetes diagnosis and require frequent glucose adjustments. Coverage applies to those using insulin or those who have a documented history of significant hypoglycemia (low blood sugar), even if they do not use insulin.
Does Medicare cover CGM for Type 2 diabetes patients not on insulin?
Yes, under the 2024 expanded guidelines, Type 2 patients who do not use insulin can qualify if they have a history of Level 2 or Level 3 hypoglycemia. This removes the old requirement of needing multiple daily insulin injections.
Is a CGM covered under Medicare Part B or Part D?
Most CGMs are covered under Part B as Durable Medical Equipment. However, some Medicare Advantage and Part D plans cover these devices as a pharmacy benefit. The billing and out-of-pocket costs will depend on which part of Medicare is used.
How much is the out-of-pocket cost for a CGM with Medicare?
Under Part B, you typically pay 20% of the Medicare-approved amount after meeting your annual deductible. Under Part D, costs vary by plan, but starting in 2026, there will be a $2,100 annual out-of-pocket cap for all covered prescription drugs and supplies.
What documentation does a doctor need to provide for Medicare CGM coverage?
A doctor must provide a written prescription, a Certificate of Medical Necessity, and clinical notes documenting your diabetes management. They must also confirm that you are being seen every six months to evaluate the effectiveness of the CGM in your treatment plan.
